| Scenario | Incremental cost per QALY gained ($CAD) |
|---|---|
| Base case analysis (reference) | 11 990 |
| Time horizon, yr | |
| 1 | 91 080 |
| 3 | 20 540 |
| 10 | 11 491 |
| 15* | 12 877 |
| MT with reduced mortality risk (odds ratio of mortality, MT + IVT v. IVT alone, 0.80) | 22 891 |
| Extra cost of MT treatment, $CAD | |
| 10 000 | Dominant |
| 20 000 | 35 779 |
| Age group, yr | |
| ≤ 70 | 4 429 |
| > 70 | 29 899 |
| Health utility in functional independence and disability states | |
| Lower limit of 95% CI | 12 366 |
| Upper limit of 95% CI | 11 809 |
| Annual discount rate for both cost and utility, % | |
| 0 | 10 028 |
| 3 | 11 205 |
| 10 | 13 943 |
| Including cost for end-of-life care for those who survive at 90 d after an acute ischemic stroke | 4 212 |
Note: $CAD = Canadian dollars in 2015, CI = confidence interval, IVT = intravenous thrombolysis, MT = mechanical thrombectomy, QALY = quality-adjusted life-year.
*About 5.4% and 6.9% of patients were alive in the IVT alone and IVT + MT arms, respectively, at 15 yr follow-up in our model.